Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Hypertension portopulmonaire“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Hypertension portopulmonaire" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Hypertension portopulmonaire"
Chabot, F., E. Gomez, L. Boyer, A. Kheir, J. Le Pavec, O. Sitbon und P. Herve. „Hypertension portopulmonaire“. Revue des Maladies Respiratoires 23, Nr. 6 (Dezember 2006): 629–41. http://dx.doi.org/10.1016/s0761-8425(06)72078-2.
Der volle Inhalt der QuelleMagois, E., J. C. Glerant, I. Mayeux, B. Toublanc, D. Mispelaere und V. Jounieaux. „134 Hypertension artérielle portopulmonaire (HTTP) et opacités pseudotumorales“. Revue des Maladies Respiratoires 21 (Januar 2004): 61. http://dx.doi.org/10.1016/s0761-8425(04)71760-x.
Der volle Inhalt der QuelleHalim, A., A. O. Daher, M. N. Guèye, S. Diallo, M. Bodian, M. P. Fall, M. A. Thioubou, M. L. Bassène, S. Fall und M. L. Diouf. „Hypertension portopulmonaire révélant une cirrhose d’origine auto-immune : à propos d’un cas“. Journal Africain d'Hépato-Gastroentérologie 10, Nr. 4 (16.09.2016): 217–19. http://dx.doi.org/10.1007/s12157-016-0677-1.
Der volle Inhalt der QuelleSaleemi, Sarfraz. „Portopulmonary hypertension“. Annals of Thoracic Medicine 5, Nr. 1 (2010): 5. http://dx.doi.org/10.4103/1817-1737.58953.
Der volle Inhalt der QuelleHopps, Eugenia, Amelia Valenti und Gregorio Caimi. „Portopulmonary Hypertension“. Clinical & Investigative Medicine 34, Nr. 3 (01.06.2011): 111. http://dx.doi.org/10.25011/cim.v34i3.15182.
Der volle Inhalt der QuelleLv, Yong, Guohong Han und Daiming Fan. „Portopulmonary hypertension“. Scandinavian Journal of Gastroenterology 51, Nr. 7 (22.03.2016): 795–806. http://dx.doi.org/10.3109/00365521.2016.1157895.
Der volle Inhalt der QuelleMukhtar, Nizar A., und Oren K. Fix. „Portopulmonary Hypertension“. Journal of Clinical Gastroenterology 45, Nr. 8 (September 2011): 703–10. http://dx.doi.org/10.1097/mcg.0b013e31820656bd.
Der volle Inhalt der QuelleLe Pavec, Jérôme, Rogério Souza, Philippe Herve, Didier Lebrec, Laurent Savale, Colas Tcherakian, Xavier Jaïs et al. „Portopulmonary Hypertension“. American Journal of Respiratory and Critical Care Medicine 178, Nr. 6 (15.09.2008): 637–43. http://dx.doi.org/10.1164/rccm.200804-613oc.
Der volle Inhalt der QuelleWatherald, Jason, Olivier Sitbon und Laurent Savale. „Portopulmonary Hypertension“. Seminars in Respiratory and Critical Care Medicine 38, Nr. 05 (Oktober 2017): 651–61. http://dx.doi.org/10.1055/s-0037-1606251.
Der volle Inhalt der QuelleDuBrock, Hilary M., Reena J. Salgia, Norman L. Sussman, Sonja D. Bartolome, Zakiyah Kadry, David C. Mulligan, Sarah Jenkins et al. „Portopulmonary Hypertension“. Transplantation Direct 5, Nr. 6 (Juni 2019): e456. http://dx.doi.org/10.1097/txd.0000000000000900.
Der volle Inhalt der QuelleDissertationen zum Thema "Hypertension portopulmonaire"
Le, Pavec Jérôme. „Hypertension portopulmonaire : aspects cliniques et biologiques“. Paris 11, 2008. http://www.theses.fr/2008PA11T026.
Der volle Inhalt der QuelleRobert, Fabien. „Étude du BMP-9 et du PlGF dans la physiopathologie du syndrome hépatopulmonaire : À la recherche de cibles thérapeutiques“. Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASQ054.
Der volle Inhalt der QuelleHepatopulmonary syndrome (HPS) is a severe pulmonary complication caused by liver diseases. It is characterized by abnormal proliferation and dilation of the small blood vessels in the lungs, leading to reduced blood oxygenation. Currently, liver transplantation is the only available treatment for this condition. Understanding the mechanisms involved in both the development and progression of HPS is crucial for developing more effective treatments. During this PhD, we explored two promising therapeutic targets. The first is BMP-9, a protein whose loss is necessary for the development of the disease. The second is PlGF, a protein that increases specifically in the context of cirrhosis and can worsen blood oxygenation issues. These new avenues could lead to the development of more targeted treatments for HPS
Shimozono, Emica 1962. „Estudo retrospectivo da prevalência da hipertensão portopulmonar, complicações intraoperatórias e sobrevida em pacientes submetidos a transplante de fígado“. [s.n.], 2014. http://repositorio.unicamp.br/jspui/handle/REPOSIP/312715.
Der volle Inhalt der QuelleDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-24T17:26:07Z (GMT). No. of bitstreams: 1 Shimozono_Emica_M.pdf: 4271192 bytes, checksum: ec937b4448d3157cccab1d06c8b5a8d3 (MD5) Previous issue date: 2014
Resumo: A Hipertensão Portopulmonar (HPP) é caracterizada pelo desenvolvimento da hipertensão arterial pulmonar associada à hipertensão portal, com ou sem doença hepática. É definida como pressão arterial pulmonar média (PAPM) acima de 25 mmHg, resistência vascular pulmonar (RVP) acima de 240 dinas.s.cm?? e a pressão de oclusão da artéria pulmonar (POAP) normal, menor de 15 mmHg. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo a sua prevalência estimada entre 2 - 6%. A mortalidade é diretamente proporcional à medida da pressão arterial pulmonar média e da resistência vascular pulmonar. Alguns estudos sugerem que a pressão da artéria pulmonar média pré-operatória seja um preditor independente para mortalidade, e muitos centros consideram que pressão arterial pulmonar média acima de 50 mmHg seja uma contraindicação absoluta para o transplante de fígado (TF). Objetivo: Analisar a prevalência, as complicações e a sobrevida dos pacientes portadores de HPP submetidos a transplante de fígado. Método: Foram analisados de modo retrospectivo, prontuários e o banco de dados da Unidade de Transplante Hepático do Hospital de Clínicas da Universidade Estadual de Campinas dos pacientes submetidos a transplante de fígado, num período de 21 anos. Dividiu-se a população em dois grupos de acordo com as medidas da pressão da artéria pulmonar média: PAPM ? 25 mmHg e PAPM > 25 mmHg. Foram estudados os exames pré-operatórios, as variáveis hemodinâmicas, bem como as complicações intraoperatórias, eventos relacionados e a sobrevida. Resultado: Foram encontrados 50 casos com PAPM > 25 mmHg e apenas um caso preencheu os critérios diagnósticos de PAPM > 25 mmHg, RVP > 240 dinas.s.cm-5 e POAP < 15 mmHg , de acordo com a European Respiratory Society Task Force on Pulmonary Hepatic Vascular Disorders (2004), e dois casos de PAPM > 50 mmHg que tiveram os procedimentos suspensos, portanto a nossa prevalência da HPP em pacientes submetidos a TF foi de 0,25%. As complicações intraoperatórias foram semelhantes nos dois grupos. A sobrevida no grupo PAPM > 25 mmHg foi menor que no grupo PAPM ? 25 mmHg. Conclusão: A prevalência da HPP observada foi menor que a descrita na literatura, ou seja, 50 (12,9%) pacientes apresentaram PAPM > 25 mmHg, sendo que destes, 49 (12,6%) apresentaram resistência vascular pulmonar < 240 dinas.s.cm-5, portanto sem HPP, e provavelmente tratava-se de circulação hiperdinâmica e/ou sobrecarga de volume. O fato de o paciente apresentar pressão arterial pulmonar média maior que 25 mmHg, não influenciou na sobrevida do enxerto
Abstract: Portopulmonary hypertension (PPH) is characterized by the development of pulmonary artery hypertension associated with portal hypertension, with or without liver disease. It is defined as a mean pulmonary artery pressure (MPAP) above 25 mmHg, pulmonary vascular resistance (PVR) above 240 dynes.s.cm-5 and the pulmonary capillary wedge pressure (PCWP) normal under 15 mmHg. The association of pulmonary hypertension with cirrhosis and portal hypertension is underdiagnosed, with an estimated prevalence of two to 6%. The mortality is directly proportional to the measured mean pulmonary artery pressure and pulmonary vascular resistance. Some studies suggest that the mean pulmonary artery pressure preoperatively is an independent predictor for mortality, and many centers consider that the mean pulmonary artery pressure above 50 mmHg is one absolute contraindication for liver transplantation (LT). Objective: To analyze the PPH prevalence, complications and survival in patients undergoing liver transplantation. Method: We analyzed retrospectively, records and data base from the Liver Transplantation Unit of the Clinical Hospital of UNICAMP of patients undergoing liver transplantation, a 21 year period. The population was separated into two groups according to the measurements of mean pulmonary artery pressure: MPAP ? 25 mmHg and MPAP > 25 mmHg. We studied the preoperative examinations, hemodynamic variables, as well as intraoperative complications, related events to PPH and survival. Result: We found 50 cases with MPAP > 25 mmHg, and one case met the diagnostic criteria for MPAP > 25 mmHg, PVR > 240 dynes.s.cm-5 and PCWP < 15 mmHg, according to European Respiratory Society Task Force on Pulmonary Hepatic Vascular Disorders (2004), and two cases of MPAP > 50 mmHg who had the procedure canceled, so our PPH prevalence in patients undergoing LT was 0,25%. The intraoperative complications were similar in both groups. The survival in group MPAP > 25 mmHg was lower than in group MPAP ? 25 mmHg. Conclusion: The prevalence rate observed was lower than described in literature, that is, 50 (12,9%) patients showed MPAP > 25 mmHg, and 49 (12,6%) of these patients had pulmonary vascular resistance < 240 dynes.s.cm-5 and therefore no PPH. This was probably due to hyperdynamic circulation and/or volume overload. The fact that mean pulmonary artery pressure was > 25 mmHg in these patients had no influence on graft survival
Mestrado
Fisiopatologia Cirúrgica
Mestra em Ciências
Buchteile zum Thema "Hypertension portopulmonaire"
Cartin-Ceba, Rodrigo, und Michael J. Krowka. „Portopulmonary Hypertension“. In Complications of Cirrhosis, 177–86. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13614-1_19.
Der volle Inhalt der QuelleCartin-Ceba, Rodrigo, und Michael J. Krowka. „Portopulmonary hypertension“. In Cirrhosis: A practical guide to management, 212–24. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118412640.ch19.
Der volle Inhalt der QuelleAhmad, Jawad. „Portopulmonary Hypertension“. In Mount Sinai Expert Guides: Hepatology, 263–70. Oxford, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118748626.ch24.
Der volle Inhalt der QuelleCartin-Ceba, Rodrigo, Vivek N. Iyer und Michael J. Krowka. „Hepatopulmonary Syndrome and Portopulmonary Hypertension“. In Contemporary Liver Transplantation, 1–23. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-05543-5_10-1.
Der volle Inhalt der QuelleCartin-Ceba, Rodrigo, Vivek N. Iyer und Michael J. Krowka. „Hepatopulmonary Syndrome and Portopulmonary Hypertension“. In Contemporary Liver Transplantation, 1–24. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-05543-5_10-2.
Der volle Inhalt der QuelleKochar, Rajan, und Michael B. Fallon. „Hepatopulmonary syndrome and portopulmonary hypertension“. In Textbook of Clinical Gastroenterology and Hepatology, 751–56. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781118321386.ch101.
Der volle Inhalt der QuelleRamsay, Michael. „Portopulmonary Hypertension and Hepatopulmonary Syndrome“. In Anesthesia and Perioperative Care for Organ Transplantation, 427–39. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6377-5_33.
Der volle Inhalt der QuelleSavale, Laurent, Philippe Hervé und Olivier Sitbon. „Portopulmonary Hypertension and Hepatopulmonary Syndrome“. In Pulmonary Vascular Disorders, 113–21. Basel: S. KARGER AG, 2012. http://dx.doi.org/10.1159/000335090.
Der volle Inhalt der QuelleCartin-Ceba, Rodrigo, Vivek N. Iyer und Michael J. Krowka. „Hepatopulmonary Syndrome and Portopulmonary Hypertension“. In Contemporary Liver Transplantation, 189–209. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-07209-8_10.
Der volle Inhalt der QuelleOkajima, Hideaki. „Long-Term Complications: Portopulmonary Hypertension“. In Introduction to Biliary Atresia, 247–54. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-2160-4_36.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Hypertension portopulmonaire"
Savale, Laurent, Romain Magnier, Jérôme Le Pavec, Dermot S. O'Callaghan, Xavier Jaïs, Delphine Natali, Marc J. C. Humbert, Gerald Simonneau und Olivier Sitbon. „Impact Of Pulmonary Arterial Hypertension Specific Therapy On Portopulmonary Hypertension“. In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3339.
Der volle Inhalt der QuelleConnolly, M., R. J. White und D. Lachant. „Resolution of Portopulmonary Hypertension After Liver Transplantation“. In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3540.
Der volle Inhalt der QuelleChickmagalur, S., K. Reiling, C. Chartan, N. P. Varghese, N. M. Villafranco und R. Coleman. „Atypical Pediatric Presentation of Severe Portopulmonary Hypertension“. In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2287.
Der volle Inhalt der QuelleRandhawa, S., E. Griffin, M. Dhingra, M. Hiatt, J. Alberts, V. V. Noble und A. Highley. „Portopulmonary Hypertension: A Case Report with Management Considerations“. In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6788.
Der volle Inhalt der QuelleJevnikar, Mitja, Nathan Ebstein, Xavier Jais, Athenais Boucly, David Montani, Marc Humbert, Olivier Sitbon und Laurent Savale. „Efficacy and safety of tadalafil in portopulmonary hypertension“. In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa3050.
Der volle Inhalt der QuelleGregonis, Erica L., Gregory R. White, Alex G. Duarte, Nahal Boroumand und Abida Haque. „Prevalence Of Portopulmonary Hypertension: A Clinico-Pathologic Assessment“. In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1922.
Der volle Inhalt der QuelleMai, E., J. Gomez-Arroyo, A. Pillai, C. Zhou, K. Snapp, S. Demetrio, D. Kay et al. „CT-derived vascular pruning assessment in portopulmonary hypertension“. In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.1526.
Der volle Inhalt der QuelleLe Pavec, J., B. Girerd, D. Montani, F. Perros, L. Savale, G. Simonneau, O. Sitbon und M. Humbert. „Circulating Dendritic Cells in Idiopathic Pulmonary Arterial Hypertension and Cirrhotic Portopulmonary Hypertension.“ In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4289.
Der volle Inhalt der QuelleLacoste-Palasset, Thomas, Antoine Beurnier, Audrey Baron, Marie-Caroline Certain, Xavier Jaïs, Anne Roche, David Montani, Marc Humbert, Olivier Sitbon und Laurent Savale. „Impact of pulmonary arterial hypertension therapies on gas exchange in portopulmonary hypertension“. In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa1766.
Der volle Inhalt der QuelleSpyropoulos, J., G. Boutsalis und K. Hanley. „Improving Management of Portopulmonary Hypertension: Effectiveness of Online CME“. In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3777.
Der volle Inhalt der Quelle